Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3059718 | 0.92 | OPRD1 (0.45) | SLC7A5OPRM1OPRD1OPRK1 | |
| SCHEMBL3059726 | 0.92 | OPRD1 (0.45) | SLC7A5OPRM1OPRD1OPRK1 | |
| SCHEMBL30799042 | 0.89 | OPRM1 (0.43) | SLC7A5OPRM1OPRD1 | |
| SCHEMBL30051696 | 0.87 | ALDH1A1 (0.45) | SLC7A5MAPTPSMB5 | |
| SCHEMBL30082063 | 0.87 | CTSD (0.46) | — | |
| SCHEMBL31321026 | 0.87 | ECE1 (0.40) | SMN1; SMN2NPSR1OPRD1EPHX2 | |
| SCHEMBL30052710 | 0.84 | SLC7A5 (0.48) | SLC7A5OPRM1OPRD1OPRK1LARS1 | |
| SCHEMBL29349612 | 0.84 | ALDH1A1 (0.42) | SMN1; SMN2NPSR1OPRD1EPHX2 | |
| SCHEMBL3057413 | 0.84 | SLC7A5 (0.55) | SLC7A5SMN1; SMN2LARS1SLC1A3SLC1A2 | |
| SCHEMBL9359613 | 0.84 | SLC7A5 (0.55) | SLC7A5SMN1; SMN2LARS1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | SLC7A5 247/4885SMN1; SMN2 4135/4885NPSR1 2720/4885 |
| US-20220387610-A1 | PEPTIDE-CONJUGATED PRODRUGS | VIP, DNPEP, PEPD | SLC7A5 439/4885SMN1; SMN2 3023/4885NPSR1 489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.